Cwm LLC Buys 962 Shares of Amgen Inc. (NASDAQ:AMGN)

Cwm LLC boosted its position in Amgen Inc. (NASDAQ:AMGN) by 0.7% during the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 129,805 shares of the medical research company’s stock after acquiring an additional 962 shares during the period. Cwm LLC’s holdings in Amgen were worth $41,825,000 as of its most recent SEC filing.

A number of other large investors also recently modified their holdings of AMGN. Nomura Holdings Inc. bought a new position in Amgen in the 4th quarter valued at about $3,104,000. MGO One Seven LLC lifted its position in shares of Amgen by 4.4% during the fourth quarter. MGO One Seven LLC now owns 6,363 shares of the medical research company’s stock valued at $1,833,000 after purchasing an additional 268 shares in the last quarter. Northwest Wealth Management LLC purchased a new position in Amgen during the fourth quarter worth about $242,000. Creative Planning increased its stake in Amgen by 3.0% in the 4th quarter. Creative Planning now owns 162,429 shares of the medical research company’s stock valued at $46,783,000 after buying an additional 4,720 shares during the last quarter. Finally, Vivaldi Capital Management LP lifted its position in shares of Amgen by 22.8% during the 4th quarter. Vivaldi Capital Management LP now owns 1,958 shares of the medical research company’s stock worth $569,000 after buying an additional 363 shares in the last quarter. 76.50% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several research firms have recently issued reports on AMGN. Bank of America upped their target price on Amgen from $325.00 to $330.00 and gave the company a “neutral” rating in a report on Wednesday, August 7th. Royal Bank of Canada reaffirmed an “outperform” rating and set a $362.00 target price on shares of Amgen in a research report on Thursday, September 26th. Dbs Bank upgraded shares of Amgen to a “strong-buy” rating in a research report on Monday, September 16th. Argus lifted their price objective on shares of Amgen from $300.00 to $340.00 and gave the stock a “buy” rating in a research report on Thursday, June 27th. Finally, Wells Fargo & Company downgraded shares of Amgen from an “overweight” rating to an “equal weight” rating and increased their target price for the company from $320.00 to $335.00 in a research report on Wednesday, August 7th. One research analyst has rated the stock with a sell rating, eleven have assigned a hold rating, twelve have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $326.30.

Amgen Stock Performance

NASDAQ AMGN opened at $322.41 on Thursday. The company’s 50 day simple moving average is $326.66 and its two-hundred day simple moving average is $310.06. The stock has a market capitalization of $172.95 billion, a PE ratio of 46.06, a P/E/G ratio of 2.98 and a beta of 0.61. The company has a debt-to-equity ratio of 9.64, a current ratio of 1.26 and a quick ratio of 0.89. Amgen Inc. has a 1 year low of $249.70 and a 1 year high of $346.85.

Amgen (NASDAQ:AMGN) last posted its quarterly earnings data on Tuesday, August 6th. The medical research company reported $4.97 earnings per share (EPS) for the quarter, missing the consensus estimate of $5.01 by ($0.04). Amgen had a net margin of 10.12% and a return on equity of 161.72%. The business had revenue of $8.39 billion for the quarter, compared to the consensus estimate of $8.35 billion. Amgen’s quarterly revenue was up 20.1% on a year-over-year basis. During the same period in the prior year, the business posted $5.00 EPS. Analysts predict that Amgen Inc. will post 19.49 earnings per share for the current fiscal year.

Amgen Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, August 6th. Investors of record on Friday, August 16th were given a $2.25 dividend. This represents a $9.00 annualized dividend and a dividend yield of 2.79%. The ex-dividend date of this dividend was Friday, August 16th. Amgen’s dividend payout ratio (DPR) is 128.57%.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.